Leon O. Jacobson Professor of Medicine, University of Chicago Medicine
Oncology
Dr. Mark J. Ratain, MD
|
|
Give Review
Mark Ratain is an expert in the field of Oncology. He went to medical school at Yale University School of Medicine. Yale University School of Medicine is a top medical university. Yale University School of Medicine is ranked 7/57 in Research/PrimaryCare. He received awards:"America's Top Doctors", "Chicago Magazine: Top Doctors", "Spotlight on Science Featured Speaker", "America's Top Doctors for Cancer", "Visiting Professor, Food and Drug Administration", "Special Recognition", "Robert Hart Waldman, M.D., Lecture", "Translational Research Professorship", "Certificate of Appreciation", "Honorary Fellow", "Rawls-Palmer Progress in Medicine Award", "Henry T. Lynch Lectureship in Medical Genetics", "Directors Service Award", "Research Achievement Award in Clinical Pharmacology and Translational Research", "Emil J. Freireich Award for Clinical Research", "Institute for Pharmacogenomics and Individualized Therapy Clinical Service Award", "Fellow (FASCO)", "Elected to Association of American Physicians", "Statesman Award", "Chair, 60th Annual Senior Scientific Session", "Americas Top Doctors for Cancer (Castle Connolly)", "Special Recognition Award", "Top Membership Recruiter", "Top Doctors: Chicago Metro Area (Castle Connolly)", "Leon O. Jacobson Professorship", "Distinguished Lecturer", "Honorary Visiting Expert", "Americas Top Doctors (Castle Connolly)", "Chicagos Top Doctors", "The Best Doctors in America (Woodward/White)", "Trainee Award", "Dreyfus Fellowship" and "Super Doctor". Doctor Mark J. Ratain, MD is a published MD as well. He has 100 publications published. The latest was: Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Mark J. Ratain accepts Medicare payments and is listed with Medicare.gov.
Publications
- Taking a Measured Approach to Toxicity Data in Phase I Oncology Clinical Trials.
- Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide.
- In vitro glucuronidation of aprepitant: a moderate inhibitor of UGT2B7.
- Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee.
- A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced Myeloid neoplasia.
- Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of pazopanib.
- Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate Cancer treated on Cancer and Leukemia Group ...
- Targeted therapies: Redefining the primary objective of phase I oncology trials.
- Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic Cell transplantation; an alliance study (CALGB 10503, 19808, and 100103).
- Incorporating biomarkers into drug labeling.
- Establishment of CYP2D6 reference samples by multiple validated genotyping platforms.
- The development of a financial toxicity patient-reported outcome in Cancer: The COST measure.
- Forecasting Unanticipated Consequences of "The Sunshine Act": Mostly Cloudy.
- Vatalanib population pharmacokinetics in patients with myelodysplastic Syndrome (MDS): CALGB 10105 (Alliance).
- Sorafenib Dose Escalation is Not Uniformly Associated with Blood Pressure Elevations in Normotensive Patients with Advanced Malignancies.
- Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance).
- First-in-human Phase I Study of Lurbinectedin (PM01183) in Patients with Advanced Solid Tumors.
- Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies.
- Challenges in interpreting the evidence for genetic predictors of ototoxicity.
- A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469.
- Germline Variants and Advanced ColoRectal Adenomas: Adenoma Prevention with Celecoxib Trial Genome-wide Association Study.
- Evaluation of utility of pharmacokinetic studies in phase I trials of two oncology drugs.
- Functional characterization of ABCC2 promoter polymorphisms and allele-specific expression.
- Hepatocyte Nuclear Factor 1 Regulates the Expression of the Organic Cation Transporter 1 via Binding to an Evolutionary Conserved Region in Intron 1 of the OCT1 Gene.
- Institutional Profile: University of Chicago Center for Personalized Therapeutics: research, education and implementation science.
- Are drug labels static or dynamic?
- Unmet needs in preventing adverse drug-drug interactions.
- CYP2D6 Genotype and Tamoxifen Activity: Understanding Interstudy Variability in Methodological Quality.
- Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel antiCancer agent ABT-751.
- Evaluation of Food Effect on Pharmacokinetics of Vismodegib in Advanced Solid Tumor Patients.
- Estimation of renal Cell carcinoma treatment effects from disease progression modeling.
- Playing Russian roulette with tyrosine kinase inhibitors.
- The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and Neutropenia: CALGB 60805 (Alliance).
- Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy.
- Unsupported off-label chemotherapy in metastatic colon Cancer.
- Cancer pharmacogenomics: strategies and challenges.
- Models of exCellence: improving oncology drug development.
- The 1200 Patients Project: Creating a New Medical Model System for Clinical Implementation of Pharmacogenomics.
- Phase I Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients.
- Might Cigarettes Be a "Smoking Gun" to Reduce Taxane Myelotoxicity?
- Value-based insurance design: aligning incentives, benefits, and evidence in oncology.
- A genome-wide association study of overall survival in pancreatic Cancer patients treated with gemcitabine in CALGB 80303.
- Oncology Micro-Cap Stocks: Caveat Emptor!
- Flushing Oral Oncology Drugs Down the Toilet.
- The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients.
- Opportunities and challenges in the development of experimental drug combinations for Cancer.
- Randomized Phase II Trials: A Long-term Investment With Promising Returns.
- Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial.
- Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer.
- Identification, replication, and functional fine-mapping of expression quantitative trait Loci in primary human Liver tissue.
- Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies.
- Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung Cancer, with a predominant effect on exon 19 microdeletions.
- Current dilemmas in Carboplatin dosing.
- Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.
- Analysis of the yield of phase II combination therapy trials in medical oncology.
- Anaplastic lymphoma kinase inhibition in non-small-cell lung Cancer.
- A pharmacogenetic study of vorinostat glucuronidation.
- A phase I study of continuous infusion cilengitide in patients with solid Tumors.
- Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology proDucts.
- Bar the windows but open the door to randomization.
- Vascular endothelial growth factor pathway.
- The design of phase II clinical trials testing Cancer therapeutics: consensus recommendations from the clinical trial design task force of the national Cancer institut...
- Individualizing dosing of irinotecan.
- Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases.
- Interactions between MDM2 and TP53 Genetic Alterations, and Their Impact on Response to MDM2 Inhibitors and Other Chemotherapeutic Drugs in Cancer Cells.
- Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment.
- Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies.
- Comprehensive pharmacogenetic Analysis of irinotecan neutropenia and pharmacokinetics.
- Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301.
- A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies.
- Biomarkers in early Cancer drug development: limited utility.
- Pharmacogenetics and pharmacogenomics of antiCancer agents.
- Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.
- Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene.
- A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute Leukemia.
- Phase I study of the ribonucleotide reDuctase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients ...
- Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet?
- Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension.
- Ethical, scientific, and regulatory perspectives regarding the use of placebos in Cancer clinical trials.
- Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.
- The HapMap Resource is Providing New Insights into Ourselves and its Application to Pharmacogenomics.
- Lack of association between common polymorphisms in UGT1A9 and gene expression and activity.
- Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 Cell lines.
- Biomarkers in phase I oncology trials: signal, noise, or expensive disTraction?
- Clarification regarding "phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other ...
- Interpreting P values in pharmacogenetic studies: a call for process and perspective.
- Design of phase II Cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung Cancer.
- The investigational drug steering committee.
- The value meal: how to save $1,700 per month or more on lapatinib.
- Attitudes toward research participation and investigator conflicts of interest among advanced Cancer patients participating in early phase clinical trials.
- UGT1A1*28 genotype affects the in-vitro glucuronidation of thyroxine in human Livers.
- Phase I and pharmacokinetic study of erlotinib for solid Tumors in patients with hepatic or renal dysfunction: CALGB 60101.
- Phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties.
- Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the Lungs.
- Complementary and alternative medicine among advanced Cancer patients enrolled on phase I trials: a study of prognosis, quality of life, and preferences for decision m...
- Testing the wrong hypothesis in phase II oncology trials: there is a better alternative.
- Effects of green tea compounds on irinotecan metabolism.
- The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity.
- Searching for tissue-specific expression pattern-linked nucleotides of UGT1A isoforms.
Schools
Yale University School Of Medicine
Johns Hopkins University
University of Chicago
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Antiphospholipid Syndrome (APS)
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- Chicago Magazine: Top Doctors
- Spotlight on Science Featured Speaker
- America's Top Doctors for Cancer
- Visiting Professor, Food and Drug Administration
- Special Recognition
- Robert Hart Waldman, M.D., Lecture
- Translational Research Professorship
- Certificate of Appreciation
- Honorary Fellow
- Rawls-Palmer Progress in Medicine Award
- Henry T. Lynch Lectureship in Medical Genetics
- Director’s Service Award
- Research Achievement Award in Clinical Pharmacology and Translational Research
- Emil J. Freireich Award for Clinical Research
- Institute for Pharmacogenomics and Individualized Therapy Clinical Service Award
- Fellow (FASCO)
- Elected to Association of American Physicians
- Statesman Award
- Chair, 60th Annual Senior Scientific Session
- America’s Top Doctors for Cancer (Castle Connolly)
- Special Recognition Award
- Top Membership Recruiter
- Top Doctors: Chicago Metro Area (Castle Connolly)
- Leon O. Jacobson Professorship
- Distinguished Lecturer
- Honorary Visiting Expert
- America’s Top Doctors (Castle Connolly)
- Chicago’s Top Doctors
- The Best Doctors in America (Woodward/White)
- Trainee Award
- Dreyfus Fellowship
- Super Doctor
Education
-
University of Chicago -
Johns Hopkins University -
Yale University School of Medicine -
Harvard University
Hospital
-
University of Chicago Medical Center
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1255494779 |
| Last Name Of The Provider | RATAIN |
| First Name Of The Provider | MARK |
| View All |
Similar Doctors
|
|
Dr. Gini F. Fleming, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edwin Posadas, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Harvey M. Golomb, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wendy Stock, MD |
|
|
Dr. Joseph M. Baron, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dorothy Sipkins, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hedy L. Kindler, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Todd L. Zimmerman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard L. Schilsky, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Everett E. Vokes, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Olatoyosi Odenike, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lucy A. Godley, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Olufunmailyao Olopade, MD |
|
|
Dr. Christopher K. Daugherty, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Brittany Beach
This Doctor is OpenDoctor Recommended.
|